While all the AI model buzz is centered on coding right now, OpenAI just released its first frontier reasoning model built purely for scientists.
Called GPT-Rosalind, this life sciences model is purpose-built for lab workflows. It has an in-depth understanding of genomics, chemistry, and protein engineering, and it's especially designed to support research in drug discovery, translational medicine, and biology more generally.
OpenAI believes this model will address key bottlenecks in the life sciences:
- Data volume exceeds human capacity: Biology is an extremely data‑rich field where modern tools have outpaced humans’ ability to keep up.
- Specialized knowledge across biology subfields: Deeper specialization has created silos that slow translation of insights across domains.
"On average, it takes roughly 10 to 15 years to go from target discovery to regulatory approval for new drugs in the United States, and only one in 10 drugs entering clinical trials are ultimately approved… We think there's a real opportunity to help researchers move faster through some of the most complex and time‑intensive parts of the scientific process,” the OpenAI team said in a briefing with journalists.
- The new model is named after Rosalind Franklin, the scientist who helped discover the shape of DNA.
- It's better than other AI models at science tasks. On tests that measure understanding of proteins, DNA, and chemical reactions, GPT-Rosalind scored higher than OpenAI's other models. In one test with real scientists, the AI actually performed better than 95% of human experts at predicting how certain RNA sequences work.
- It comes with special tools for scientists. OpenAI is also releasing a "Life Sciences research plugin" that connects the AI to more than 50 scientific databases and tools, so researchers can do things like look up protein structures, search DNA sequences, and review scientific papers all in one place.
- Access is limited for safety reasons. Because this technology could be misused to create something harmful, OpenAI is granting access only to approved organizations conducting legitimate research, such as Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific.
“The opportunity we set out to achieve was for every scientist to become their own research team, to tackle more by having the complementary expert-level knowledge and skills at their fingertips,” the OpenAI team shared during its press briefing.
Our Deeper View
OpenAI's GPT-Rosalind represents further evidence that today's LLMs are moving away from a one-model-to-rule-them-all approach (the AGI path) toward specialized, domain-specific, and even task-specific models. Along with Claude Mythos and GPT-5.4-Cyber, GPT-Rosalind also represents a new phase of models in which the most powerful models aren't being made broadly available to everyone, because they could also be adapted by bad actors for nefarious purposes that could cause harm. This trend, along with personal AI agents, is emerging as one of AI's key turning points of 2026.